Searching. Please wait…
1580
37
170
29264
4420
2603
347
391
Abstract: Allo-SCT is a curative option for selected patients with relapsed/refractory (R/R) MCL, but with significant NRM. We present the long-term results of patients receiving allo-SCT in Spain from March 1995 to February 2020. The primary endpoints were EFS, OS, and cumulative incidence (CI) of NRM, relapse, and GVHD. We included 135 patients, most (85%) receiving RIC. After a median follow-up of 68 months, 5-year EFS and OS were 47 and 50%, respectively. Overall and CR rates were 86 and 80%. The CI of relapse at 1 and 3 years were 7 and 12%. NRM at day 100 and 1 year were 17 and 32%. Previous ASCT and Grade 3-4 aGVHD were associated with a higher NRM. Grade 3-4 aGVHD, donor type (mismatch non-related), and the time-period 2006-2020 were independently related to worse EFS. Patients from 1995-2005 were younger, most from HLA-identical sibling donors, and were pretreated less. Our data confirmed that allo-SCT may be a curative option in R/R MCL with low a CI of relapse, although NRM is still high, being mainly secondary to aGVHD. The arrival of new, highly effective and low toxic immunotherapeutic or targeted therapies inevitably will relegate allo-SCT to those fit patients who fail these therapies, far away from the optimal timing of treatment.
Fuente: Cancers, 2022, 14(11), 2673
Publisher: MDPI
Year of publication: 2022
No. of pages: 16
Publication type: Article
DOI: 10.3390/cancers14112673
ISSN: 2072-6694
Publication Url: https://doi.org/10.3390/ cancers14112673
Consult in UCrea Read publication
GUTIERREZ, ANTONIO
BENTO, LEYRE
NOVELLI, SILVANA
MARTIN, ALEJANDRO
GUTIERREZ, GONZALO
QUERALT SALAS, MARIA
BASTOS-OREIRO, MARIANA
PEREZ, ARIADNA
HERNANI, RAFAEL
CRUZ VIGURIA, MARIA
LOPEZ-GODINO, ORIANA
MONTORO, JUAN
PIÑANA, JOSE LUIS
FERRA, CHRISTELLE
PARODY, ROCIO
MARTIN, CARMEN
ESPAÑOL, IGNACIO
LUCRECIA YAÑEZ SAN SEGUNDO
RODRIGUEZ, GUILLERMO
ZANABILI, JOUD
Back